MSD is accelerating in France.
The American laboratory announces 500 million euros in investments over the next three years.
They will be divided equally between clinical trials and production.
While MSD (known as Merck in the United States) does not have a human health factory in France, it plans to invest through local subcontractors.
After Pfizer, which announced in January 520 million euros of investment over five years, MSD is the second American laboratory to commit to this level.
"France has a leading health ecosystem, recognized hospitals, high-quality research",
said Rob Davis, president of MSD since the summer of 2021. Passing through Paris, he signed a new partnership on Tuesday with the Institut Pasteur in viral diseases such as Zika via its endowment fund, MSD Avenir (42 million euros). euro).
To discover
Taxes 2022: all about your tax return
Read also
Anti-Covid pills: the battle is brewing between the American labs MSD and Pfizer
In three years, the American laboratory has increased the number of clinical trials carried out in France by 45% (145 in progress), mainly…
This article is for subscribers only.
You have 77% left to discover.
Cultivating your freedom is cultivating your curiosity.
Keep reading your article for €0.99 for the first month
I ENJOY IT
Already subscribed?
Login
